BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...in patients with hypoxemia secondary to systemic inflammatory response syndrome due to acute pancreatitis. Meanwhile, MediciNova Inc....
...ibudilast (AV411, MN-166, AV-411) Avigan, favipiravir (T-705) Biohaven Pharmaceutical Holding Co. Ltd. Chembio Diagnostics Inc. Stony Brook University Thomas Jefferson University MediciNova Inc. CanSino...
BioCentury | Jul 12, 2019
Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

...clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's...
...for a differentiated patient population following the approval of two other new therapies this year. MediciNova Inc....
...candidate, an oral small molecule inhibitor of PDE-4, PDE-10 and MIF that suppresses pro-inflammatory cytokines. MediciNova...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...disease (HD) Preclin Cytokines/Chemokines Macrophage migration inhibitory factor (MIF) Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) / MediciNova Inc....
BioCentury | Feb 12, 2019
Distillery Therapeutics

Neurology

...in schizophrenia. Bristol-Myers Squibb Co. markets Buspar buspirone, a 5-HT1A receptor partial agonist, for anxiety. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

...open-label extension. Data were presented at the American Academy of Neurology meeting in Los Angeles. MediciNova...
...discuss next steps with FDA (see BioCentury, Aug. 8, 2016 & Feb. 2, 2018) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

...Data were presented at the American Academy of Neurology meeting in Los Angeles. Last year, MediciNova...
...is preparing for an end-of-Phase II meeting with FDA (see BioCentury, Nov. 3, 2017) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

...safety, pharmacokinetics, HDL-C, LDL-C, total cholesterol, liver enzymes and percentage of fat in the liver. MediciNova...
...ALOX5; 5-LO). It has Fast Track designation in the U.S. to treat NASH with fibrosis. MediciNova Inc....
...fat in the liver Status: Phase IIa data Milestone: NA Jennie Walters tipelukast (MN-001, kca-757) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. 5-lipoxygenase...
BioCentury | Apr 2, 2018
Clinical News

Early stop in liver disease trial boosts MediciNova

...said it will "accelerate further development" of the candidate, but did not respond to inquiries. MediciNova...
...the European Association for the Study of the Liver meeting on April 13 in Paris. MediciNova...
...Fast Track designation in the U.S. to treat NASH with fibrosis. Monday's stock move erases MediciNova's...
BioCentury | Mar 30, 2018
Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

...Los Angeles sponsored the trial in collaboration with NIH's National Institute on Drug Abuse (NIDA). MediciNova...
...to treat methamphetamine use disorder that is being conducted at Oregon Health & Science University. MediciNova...
...part of efforts to explore new endpoints for medication-assisted treatments that help achieve therapeutic benefit." MediciNova Inc....
BioCentury | Mar 29, 2018
Clinical News

MediciNova sinks after meth dependence failure

...Los Angeles sponsored the trial in collaboration with NIH's National Institute on Drug Abuse (NIDA). MediciNova...
...to treat methamphetamine use disorder that is being conducted at Oregon Health & Science University. MediciNova...
...benefit" (see BioCentury Extra, Feb. 16) . Elizabeth S. Eaton Ketas, ibudilast (AV411, MN-166, AV-411) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. National...
Items per page:
1 - 10 of 183
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...in patients with hypoxemia secondary to systemic inflammatory response syndrome due to acute pancreatitis. Meanwhile, MediciNova Inc....
...ibudilast (AV411, MN-166, AV-411) Avigan, favipiravir (T-705) Biohaven Pharmaceutical Holding Co. Ltd. Chembio Diagnostics Inc. Stony Brook University Thomas Jefferson University MediciNova Inc. CanSino...
BioCentury | Jul 12, 2019
Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

...clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's...
...for a differentiated patient population following the approval of two other new therapies this year. MediciNova Inc....
...candidate, an oral small molecule inhibitor of PDE-4, PDE-10 and MIF that suppresses pro-inflammatory cytokines. MediciNova...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...disease (HD) Preclin Cytokines/Chemokines Macrophage migration inhibitory factor (MIF) Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) / MediciNova Inc....
BioCentury | Feb 12, 2019
Distillery Therapeutics

Neurology

...in schizophrenia. Bristol-Myers Squibb Co. markets Buspar buspirone, a 5-HT1A receptor partial agonist, for anxiety. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

...open-label extension. Data were presented at the American Academy of Neurology meeting in Los Angeles. MediciNova...
...discuss next steps with FDA (see BioCentury, Aug. 8, 2016 & Feb. 2, 2018) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

...Data were presented at the American Academy of Neurology meeting in Los Angeles. Last year, MediciNova...
...is preparing for an end-of-Phase II meeting with FDA (see BioCentury, Nov. 3, 2017) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

...safety, pharmacokinetics, HDL-C, LDL-C, total cholesterol, liver enzymes and percentage of fat in the liver. MediciNova...
...ALOX5; 5-LO). It has Fast Track designation in the U.S. to treat NASH with fibrosis. MediciNova Inc....
...fat in the liver Status: Phase IIa data Milestone: NA Jennie Walters tipelukast (MN-001, kca-757) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. 5-lipoxygenase...
BioCentury | Apr 2, 2018
Clinical News

Early stop in liver disease trial boosts MediciNova

...said it will "accelerate further development" of the candidate, but did not respond to inquiries. MediciNova...
...the European Association for the Study of the Liver meeting on April 13 in Paris. MediciNova...
...Fast Track designation in the U.S. to treat NASH with fibrosis. Monday's stock move erases MediciNova's...
BioCentury | Mar 30, 2018
Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

...Los Angeles sponsored the trial in collaboration with NIH's National Institute on Drug Abuse (NIDA). MediciNova...
...to treat methamphetamine use disorder that is being conducted at Oregon Health & Science University. MediciNova...
...part of efforts to explore new endpoints for medication-assisted treatments that help achieve therapeutic benefit." MediciNova Inc....
BioCentury | Mar 29, 2018
Clinical News

MediciNova sinks after meth dependence failure

...Los Angeles sponsored the trial in collaboration with NIH's National Institute on Drug Abuse (NIDA). MediciNova...
...to treat methamphetamine use disorder that is being conducted at Oregon Health & Science University. MediciNova...
...benefit" (see BioCentury Extra, Feb. 16) . Elizabeth S. Eaton Ketas, ibudilast (AV411, MN-166, AV-411) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. National...
Items per page:
1 - 10 of 183